NetworkNewsBreaks Archive - Page 1860 of 1993

FridaySep 01, 2017 11:09 am

NetworkNewsBreaks – InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) Could Prove to Be a Cannabis Biotech Unicorn

The recent solar eclipse that enthralled the world has come and gone, but no shadow of an eclipse is on the horizon to blot out the progress of InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). As peer valuations have soared in Canada’s cannabis market, InMed continues its promising R&D efforts into the therapeutic benefits of marijuana, and this Vancouver, Canada-based company may just prove to be one of the unicorns of Canada’s cannabis biotech market. An excerpt from an article further discussing this reads: “InMed Pharmaceuticals has more to offer than the typical drug discovery and development company. Its triple…

FridaySep 01, 2017 11:06 am

NetworkNewsBreaks – India Globalization Capital (NYSE: IGC) a Dark Horse in the Race to Treat Alzheimer’s

Alzheimer’s is the most expensive disease in the United States, and pharmaceutical companies are racing to find viable treatments for this devastating disease, which currently affects more than 5.3 million Americans and their loved ones. Wall Street is placing bets on who will win the race to treat Alzheimer’s, and India Globalization Capital (NYSE MKT: IGC) is one promising candidate with a compelling patent-pending treatment protocol. An excerpt from an article further discussing this reads: “IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of…

ThursdayAug 31, 2017 12:37 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on August 31, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: EXFO 6.25% – News: Inks deal to acquire a 33.1% equity stake in Astellia KMPH 6.03% – News: Presenting at the Rodman & Renshaw 19th Annual Global Investment Conference on September 11 CRIS 4.30% – News: Presenting at the ESMO 2017 Congress on September 11 RXII 3.51% – News: Presenting at the 8th Annual Investing for Cures Forum on September 7 NDLS 3.42% – News: Partners with No Kid Hungry® to help end childhood…

ThursdayAug 31, 2017 12:31 pm

NetworkNewsBreaks – Dextera Surgical, Inc.’s (NASDAQ: DXTR) MicroCutter 5/80™ Receives Expanded Indication Approval by FDA; Shares Higher

Dextera Surgical (NASDAQ: DXTR) shares are up 15% this morning after the company said it has received approval from the U.S. Food and Drug Administration (FDA) to use its MicroCutter 5/80 Stapler and MicroCutter 30 White and Curved Tip White Reloads in combination with open solid organ parenchymal dissection techniques, including such organs as the liver, kidney, pancreas and spleen. “This expanded indication represents an additional 44,000 procedures in the United States annually, and we look forward to bringing the MicroCutter 5/80 to surgeons for these applications,” Dextera Surgical president and CEO Julian Nikolchev stated in the news release. To…

ThursdayAug 31, 2017 12:29 pm

NetworkNewsBreaks – Apricus Biosciences, Inc.’s (NASDAQ: APRI) Vitaros™ Class 2 NDA Resubmission Acknowledged by FDA; PDUFA Goal Date Set

Apricus Biosciences (NASDAQ: APRI) this morning said that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its recently resubmitted New Drug Application (NDA) for Vitaros™ and considers it a complete, class 2 response to Apricus’ 2008 action letter. Additionally, the PDUFA (Prescription Drug User Fee Act) goal date for conclusion of the FDA’s review is set for the standard review period for NDA resubmissions of six months, falling on February 17, 2018. “The FDA has determined that the resubmission is a complete, class 2 response to our 2008 action letter. Importantly, we believe that Vitaros, if approved, will…

ThursdayAug 31, 2017 12:27 pm

NetworkNewsBreaks – SteadyMed (NASDAQ: STDY) Shares Plunge on Refusal to File Letter from FDA for Trevyent® NDA

SteadyMed (NASDAQ: STDY) shares are down 35% this morning after the company said it has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) related to its New Drug Application (NDA) for Trevyent®. The Trevyent NDA was submitted in June 2017 for the treatment of Pulmonary Arterial Hypertension (PAH). Upon preliminary review of the NDA, the FDA determined that it was not adequately complete to permit a substantive review. The FDA has requested more details regarding certain device specifications and performance testing. The FDA also requested further design verification and validation testing on the final,…

ThursdayAug 31, 2017 9:19 am

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Clinical Study of High Absorption TurboCBD™ Product

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product. The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers. “Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of…

WednesdayAug 30, 2017 1:15 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on August 30, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: NBEV 19.24% – News: Expands Marley yerba Mate™ with distribution partners throughout the US FTEK 14.14% – News: Receives multiple APC contracts totaling $6.9M SUMR 6.47% – News: Names new member to board of directors CRME 5.60% – News: Presents new data regarding BRINAVESS at European Society of Cardiology Congress 2017 EVLV 5.21% – News: Agrees to sell WWDP for $13.5M ICAD 3.91% – News: Obtains approval of Xoft Axxent balloon applicators from the…

WednesdayAug 30, 2017 1:14 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage, Increase PT on FTE Networks, Inc. (FTNW)

SeeThruEquity has updated its coverage and increased its price target to $3.20 on shares of FTE Networks, Inc.’s (OTCQX: FTNW) stock following the company’s recent report of financial results for the second quarter of 2017. FTE completed the acquisition of Benchmark Builders, Inc. in April, which contributed to its reported revenues of $50.2 million for the second quarter, a massive increase compared to $3.2 million for the same period of 2016. In addition to contributing to revenues, the company’s acquisition of Benchmark also expands its service capabilities and almost doubles its sales backlog. For more information, visit www.ftenet.com About FTE…

WednesdayAug 30, 2017 1:12 pm

NetworkNewsBreaks – Otonomy, Inc. (NASDAQ: OTIC) Misses Primary Endpoint in AVERTS-1 Phase 3 Trial; Shares Hit New 52-Week Low

Shares of Otonomy, Inc. (NASDAQ: OTIC) plummeted 81% to a new year-low of $3.80 this morning, a drastic fall below its previous low of $11.30, as investors reacted to news that the company reported negative results for its AVERTS-1 phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease. The clinical trial missed the primary endpoint and all key vertigo secondary endpoints. Shares of OTIC now trade in a 52-week range of $3.80-$21.15. “Based on these results, we are immediately suspending all development activities for OTIVIDEX including the ongoing AVERTS-2 trial. In addition, the company is undertaking a review…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks